Abbvie

This study follows about 200 adults with moderate to severe ulcerative colitis who are prescribed risankizumab by their doctors. Researchers will track how well the drug controls symptoms like bleeding and diarrhea over 52 weeks. The goal is to see how effective and safe the trea…

This study tests an oral medication called upadacitinib for people with severe alopecia areata, a condition where the immune system attacks hair follicles, causing hair loss. About 1,500 adults and teens will receive either the drug or a placebo daily for up to 160 weeks. The mai…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease as well as standard eye injections given every few weeks. About 714 adults aged…

This study tests two drugs (risankizumab and lutikizumab) alone or together in 120 adults with active psoriatic arthritis, a condition causing joint pain and swelling. Participants are randomly assigned to one of three treatment groups. The goal is to see if these targeted therap…

This study tests an experimental drug called ABBV-319 in adults with certain blood cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have come back or stopped responding to treatment. The main goals are to check the drug's safety, …

This study tests a gel stent device to lower eye pressure in people with glaucoma, a leading cause of blindness. About 130 adults aged 45 and older will receive the implant through one of two surgical methods. Researchers will check safety and how well the stent reduces eye press…

This study looks at how safe and effective the drug upadacitinib is for people with moderate to severe Crohn's disease in everyday medical practice in Japan. About 240 participants will take the drug as prescribed by their doctor and be followed for up to 64 weeks. The goal is to…

This study tests an oral drug, upadacitinib, in children aged 2 to 18 with moderate-to-severe Crohn's disease who haven't improved with other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like belly pain and diarrhea. The trial has th…

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or not improved after prior therapy. About 380 participants will be randomly assigned to receive either etentamig or a standard therapy chosen by their doct…

This early-stage trial tests an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check safety and how the drug moves through the body. Participants rece…

This early-phase study tests a single dose of ABBV-519 in about 30 adults with moderate lupus or rheumatoid arthritis. The main goals are to check how the drug moves through the body, how it affects immune cells, and whether it is safe. Participants will be followed for about a y…

This study tests a medicine called risankizumab in children with juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 kids will get either risankizumab or the standard drug adalimumab for up to 2 years. The goal is to see if risankizumab safely impr…

This study tests a one-time gene therapy called surabgene lomparvovec for people with diabetic retinopathy, an eye disease caused by diabetes that can lead to blindness. About 576 adults with moderate to severe non-proliferative diabetic retinopathy will receive either the gene t…

This study looks at how upadacitinib, an approved pill for eczema, is actually used by patients in China. About 1,000 teens and adults with moderate to severe eczema will be followed for 12 months. Researchers will track dose changes, how well patients stick to their medication, …

This study looks at how well risankizumab works for adults with moderate to severe ulcerative colitis in everyday medical care in Japan. About 200 people who are already prescribed the drug by their doctor will be followed for up to 3 years. The goal is to see if the treatment he…

This study tests whether a new combination of two experimental drugs (livmoniplimab and budigalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-squamous non-small cell lung cancer that has spre…

This study tests an investigational drug called MEDI0618 to see if it can safely reduce the number of migraine headache days in adults with episodic migraine. About 488 participants will receive either the drug or a placebo as a shot under the skin. The main goal is to compare th…

This early-stage study tests a new investigational drug called azirkitug, alone or combined with other drugs, in adults with advanced solid tumors like lung cancer, head and neck cancer, and others. The main goals are to check safety and how the drug moves through the body. About…

This study tests an investigational drug, mirvetuximab soravtansine, in people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer whose tumors have high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor cells. About 110 …

This study tests a new drug called mirvetuximab soravtansine (MIRV) combined with other medicines for people with ovarian cancer. About 400 participants will receive different doses of MIRV with either carboplatin, bevacizumab, or both. The goal is to find the safest and most eff…

This early-stage study tests an experimental drug called ABBV-438 in about 127 adults with multiple myeloma that has returned or stopped responding to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink the cancer. Partici…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for patients who have no other suitable treatment options and cannot join ongoing…

This study tests whether adding an experimental drug (telisotuzumab adizutecan) to a standard targeted therapy (osimertinib) works better than standard treatment for advanced lung cancer with an EGFR mutation. About 854 adults will receive different doses to find the safest and m…

This early-phase study tests an investigational drug called ABBV-324 in about 232 adults with liver cancer (hepatocellular carcinoma) or a type of lung cancer (squamous non-small cell lung cancer). The main goals are to check safety, find the right dose, and see if the drug shrin…

This study tests a new combination of drugs (telisotuzumab adizutecan, budigalimab, plus standard chemotherapy) for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will receive either the new combo …

This study will follow 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will track how well the drug controls symptoms like bloody diarrhea over one year. The goal is to see how effective this approv…

This study tests a new drug called etentamig combined with daratumumab against a standard treatment for multiple myeloma, a blood cancer. It is for adults newly diagnosed with the disease who are not healthy enough for a stem cell transplant. The goal is to see if the new combina…

This study tests the drug risankizumab in children aged 2 to 18 with moderate-to-severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce symptoms and gut inflammation. Participants will receive the drug by IV or injection o…

This study observes how well the drug epcoritamab works in real-world settings for adults with advanced diffuse large B-cell lymphoma or follicular lymphoma. About 700 participants will receive the drug as part of their normal care and be followed for up to 3 years. The goal is t…

This early-phase study tests an experimental drug called ABBV-711, alone or with another drug (budigalimab), in adults with advanced squamous tumors (a type of cancer). The main goals are to check safety and see if the drug shrinks tumors. About 220 participants will receive the …

This program provides early access to upadacitinib for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefits o…

This study tests a new drug called telisotuzumab adizutecan against standard care in about 140 adults with colorectal cancer who have no visible tumors after surgery but still have cancer DNA in their blood. The goal is to see if the new drug can delay or prevent the cancer from …

This study tests a one-time gene therapy called surabgene lomparvovec (ABBV-RGX-314) for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 561 adults aged 50 and older who have already been treated for nAMD will receive either the gene…

This early-stage study tests an experimental drug called ABBV-969 in men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check the drug's safety, find the righ…

This study tests an experimental drug called surzetoclax in people with multiple myeloma that has returned or stopped responding to other treatments. The drug is given alone or with standard therapies to find the best dose and check safety. About 130 adults will take part worldwi…

This study tests an experimental drug called IMGN151, alone or with other cancer treatments, in about 377 adults with gynecologic cancers like ovarian cancer. The goal is to check safety and how well the drug works. Participants receive the drug through an IV and are monitored cl…

This study tests a new drug, telisotuzumab vedotin, against a standard chemotherapy (docetaxel) in adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has a high level of a protein called c-Met. About 698 participants worldwide will be randomly a…

This study tests whether giving a targeted drug (mirvetuximab soravtansine) plus chemotherapy before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers. About 140 adults with a specific protein (FRα) on their cancer cells will receive the combination intra…

This study tests an experimental drug called ABBV-142 in people with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and makes breathing hard. About 165 adults will be randomly assigned to receive either the drug or a placebo for 52 weeks, and neithe…

This study looks at how long people with psoriatic arthritis stay on the drug risankizumab compared to other advanced treatments. It involves up to 1,200 participants across 15 countries, all receiving their usual care. The goal is to see if risankizumab helps control the disease…

This early-stage study tests an experimental drug called ABBV-901, given alone or with a standard drug (bevacizumab), in about 207 adults with ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug shrinks tumors. P…

This study tests a daily pill called upadacitinib for people with severe alopecia areata, an immune system attack on hair follicles causing at least 25% scalp hair loss. About 123 teens and adults in Japan will take either the drug or a placebo for up to 104 weeks to see if it sa…

This study tests an experimental drug, etentamig, for multiple myeloma, a blood cancer that often returns or resists treatment. About 440 adults will receive etentamig alone or with other cancer drugs to see if it is safe and works. The goal is to control the disease, not cure it…

This study tests a drug called venetoclax in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. About 110 participants will receive venetoclax to see how many achieve a significant reduction…

This study tests three new treatments (lutikizumab, ravagalimab, or both together) in about 180 adults with moderate to severe rheumatoid arthritis who have already tried 1 or 2 other biologic drugs without success. Participants will receive the study drug or a placebo and be mon…

This study tests a new drug, telisotuzumab adizutecan, combined with an immunotherapy (PD-1 inhibitor) for people with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to find the best dose and see if the combo shrinks tumors better than standard car…

This study tests a new drug, ABBV-706, combined with atezolizumab against standard treatment for people with extensive-stage small cell lung cancer that hasn't been treated yet. About 180 adults will receive either the new combo or standard care to find the best dose and see if i…

This study tests whether adding an experimental drug called telisotuzumab adizutecan to standard chemotherapy can help people with metastatic colorectal cancer. About 390 adults will receive either the new combination or standard treatment. The goal is to see if the new drug shri…

This early-stage study tests a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or not responded to treatment. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 165 participants will receive the d…

This study tests an experimental drug, etentamig (ABBV-383), in adults with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 76 participants will receive the drug by IV to see if it can control the disease and what side effects occur. The goal is t…

This study tests an experimental drug called telisotuzumab adizutecan for people with a certain type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has gotten worse after using a standard targeted therapy. About 430 adults will receive either …

This study tests an experimental oral medication, upadacitinib, in children aged 1 to 17 with a severe, body-wide form of juvenile arthritis (sJIA). About 90 participants will receive either upadacitinib or the standard injectable drug tocilizumab for 52 weeks. The goal is to see…

This study tests the drug risankizumab in children (ages 2 to 17) with moderate to severe ulcerative colitis, a condition that causes inflammation and bleeding in the colon. The goal is to see how the drug works in the body, how safe it is, and whether it can control the disease.…

This study tests four targeted medicines (risankizumab, trosunilimab, lutikizumab, and ABBV-8736) in about 540 adults with moderate to severe Crohn's disease. The goal is to see if these drugs can reduce gut inflammation and improve symptoms. Participants will receive injections …

This program provides early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regu…

This study looks at how well Foslevodopa/Foscarbidopa works in everyday life for Italian adults with advanced Parkinson's disease. About 270 participants will receive the drug as a continuous infusion under the skin for up to 12 months. The main goal is to see if their quality of…

This study tracks about 678 adults with moderate to severe rheumatoid arthritis in Germany to see how long they stay on upadacitinib (UPA) versus TNF-inhibitor drugs. Doctors chose the treatment before the study started, based on standard care. The goal is to find out which medic…

This study tests a drug called venetoclax in about 14 adults in Japan with a rare blood cancer (Waldenström macroglobulinemia) that has returned or not responded to prior therapy. Participants take venetoclax pills daily, with the dose gradually increased. The main goal is to see…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of the study drug or an approved treatment to check…

This study looks at how well the drug upadacitinib (RINVOQ) works for people with moderate to severe ulcerative colitis, a condition causing colon inflammation and bleeding. About 400 adults in Germany, Austria, and Switzerland who are already prescribed the drug will be followed…

This study tests whether upadacitinib (a daily pill) works better than dupilumab (an injection) for children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. About 675 kids worldwide will take part. The goal is to see which treatment reduces skin redne…

This study tests a daily pill called upadacitinib for adults with moderate to severe eczema (atopic dermatitis) who did not get enough relief from the injection dupilumab. About 200 participants will receive either upadacitinib or continue dupilumab for 32 weeks. The goal is to s…

This study tests whether Armour Thyroid, a natural thyroid extract, works as well as the standard synthetic T4 medication for adults with hypothyroidism (an underactive thyroid). About 2,800 participants who are already stable on synthetic T4 will be randomly assigned to continue…

This study tests whether a daily pill called ubrogepant can prevent migraines that happen around a woman's period. About 496 women with regular menstrual cycles and a history of menstrual migraine will take either the drug or a placebo for 7 days each cycle. The goal is to see if…

This study looks at how well a drug called Foslevodopa/Foscarbidopa works for people with advanced Parkinson's disease in everyday medical practice in Belgium. About 120 adults will be followed for up to 18 months while receiving the drug as prescribed by their doctor. The main g…

This study will follow 250 adults with moderate-to-severe Crohn's disease who are switching to a second-line treatment (upadacitinib or risankizumab) after a first TNF-inhibitor didn't work well enough. Researchers want to see how many patients achieve remission without needing s…

This study tests different ways to start a drug called venetoclax (given with other medicines) in people with untreated chronic lymphocytic leukemia (CLL). The goal is to find the safest dosing schedule to reduce the risk of a serious side effect called tumor lysis syndrome. Abou…

This study tests an experimental drug called telisotuzumab adizutecan in people aged 12 and older whose advanced solid tumors have a specific genetic change (MET amplification). The goal is to see if the drug shrinks tumors and to check for side effects. About 100 participants wi…

This early-stage study tests a new drug called ABBV-295 in adults with obesity. The main goal is to check safety and side effects, but researchers will also measure weight changes. About 48 participants will receive either the drug or a placebo as injections under the skin. This …

This study tests an experimental drug called telisotuzumab vedotin in adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has a high level of a protein called c-Met. About 150 participants will receive one of three different doses of the drug to …

This study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils in the armpits, groin, and genital area. It is for adults and teens who have not improved with other treatments. The trial co…

This program offers early access to an investigational drug called ABBV-706 for people with small cell lung cancer who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the possible benefits outweigh the risks for each patient. The…

This study tests whether giving a second course of the drugs venetoclax and obinutuzumab can control chronic lymphocytic leukemia (CLL) that has returned after initial treatment. About 75 adults whose CLL came back after prior venetoclax-based therapy will receive the drug combin…

This study tests a material called ARTIA, used during breast reconstruction after mastectomy. It involves 783 adults who will have immediate two-stage implant-based reconstruction. The goal is to see if ARTIA reduces complications and improves satisfaction with breast appearance …

This early-stage study tests an investigational drug called ABBV-319 in about 36 adults with lupus or Sjogren's disease. The drug targets and depletes overactive B cells, which are immune cells that drive these autoimmune conditions. The main goals are to check safety, how the dr…

This study tests two experimental drugs, etentamig and iberdomide, together in adults whose multiple myeloma has returned or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink the cancer. About 135 participants will receive diffe…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 Indian adults newly diagnosed with acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see how well the combo controls the cancer and what…

This study tests an experimental drug called etentamig (ABBV-383) in adults with multiple myeloma that has returned or not improved after prior treatments. The goal is to find the best dose and check for side effects. About 210 participants will receive the drug by IV infusion ov…

This study tests whether a daily pill called atogepant can prevent chronic migraine in teenagers aged 12 to 17. About 420 teens with frequent migraines will take either the drug or a placebo for 12 weeks. Researchers will track side effects and count how many migraine days each p…

This study tests whether a daily pill called atogepant can prevent migraines in children aged 6 to 17 who have 4 to 14 migraine days per month. About 450 participants will receive either a low dose, high dose, or placebo for 12 weeks. The goal is to see if the medicine safely red…

This study looks at the safety and effectiveness of atogepant, an approved drug, for preventing migraines in Korean adults. About 3000 people who are prescribed atogepant by their doctor will take the pill as usual and be followed for up to 12 weeks. The goal is to see how well i…

This program gives people with Parkinson's disease access to the investigational drug tavapadon before it is officially approved. A doctor must decide if the potential benefits outweigh the risks for each patient. The program is only available in certain regions and for those who…

This study tests a new injectable gel called NOA VOLUME against the well-known JUVÉDERM VOLUMA XC for restoring lost volume in the mid-face (cheek area). About 231 adults with moderate to severe cheek volume loss will receive one of the two fillers, with optional touch-ups and re…

This study tests if cariprazine, already approved for adults with bipolar depression, can safely help children aged 10 to 17 who are currently experiencing a depressive episode. About 380 participants will be randomly assigned to receive either the drug or a placebo for 6 weeks. …

This study tests an experimental drug called ABBV-932 for adults with generalized anxiety disorder (GAD) whose current antidepressants aren't working well enough. About 315 participants will receive either ABBV-932 or a placebo alongside their usual antidepressant for 6 weeks. Th…

This study tests an experimental drug called icalcaprant for treating depression in people with bipolar I or II disorder. About 195 adults will take either the drug or a placebo daily for 6 weeks. Researchers will measure mood changes and side effects to see if the drug is safe a…

This early-stage study tests a new drug called ABBV-295 in 24 healthy Japanese adults who are overweight or obese. The main goal is to check for side effects and how the drug moves through the body. Participants receive injections of the drug or a placebo, and researchers monitor…

This study looks at whether taking ubrogepant (a migraine medicine) during the earliest warning signs of a migraine—called the prodrome phase—can prevent moderate to severe headache pain. About 189 adults who already use ubrogepant will track their symptoms over 13 weeks. The goa…

This study looks at eye problems caused by mirvetuximab soravtansine, a drug for recurrent ovarian cancer. About 100 participants with high folate receptor-alpha will be monitored closely. The goal is to find better ways to prevent or manage these side effects.

This study tests a new oral drug, icalcaprant, for adults with major depressive disorder who are currently having a depressive episode. Around 195 participants will take either the drug or a placebo daily for 6 weeks. Researchers will measure changes in depression symptoms and ch…

This study looks at whether a continuous infusion of Foslevodopa/Foscarbidopa (a Parkinson's medication) can improve sleep problems in people with advanced Parkinson's disease. About 103 adults in Spain who are already prescribed this treatment by their doctor will take part. Res…

This study tests an investigational drug called emraclidine in 268 adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and confused thinking. Participants will take either emraclidine or a placebo for up to 42 days and be monitored for …

This study tests whether eluxadoline can safely improve stool consistency and reduce diarrhea in children aged 6 to 17 with irritable bowel syndrome with diarrhea (IBS-D). About 95 participants will receive either the drug or a placebo. The goal is to find the right dose and see …

This study tests a new drug, ABBV-932, to see if it is safe and tolerable for people with bipolar I or II disorder who are currently in a depressive episode. About 200 adults will take the drug as capsules for 26 weeks, followed by a 30-day safety check. The goal is to monitor si…

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will measure how the drug affects their quality of life, including skin symptoms and daily functioning, over up to 2.5 years. Participants c…

This study tests whether ubrogepant, a drug already approved for adults, can safely and effectively treat migraine headaches in children and adolescents aged 6 to 17. About 1,059 participants will receive either a low or high dose of the drug or a placebo. The main goal is to see…

This study tests a new artificial tear called ABBV-444 against an existing brand, Refresh Optive, in 250 adults with dry eye disease. Participants use the assigned eye drops for 90 days. The goal is to see if the new formula provides better symptom relief and is safe.

This study tests an investigational drug called AGN-151607-DP (gemibotulinumtoxinA) to see if it can help close the belly wall after open ventral hernia repair without needing a more complex surgery. About 200 adults with a midline ventral hernia will receive either the drug or a…

This study tests an investigational gel called ELAPR002f for adults with moderate to severe atrophic acne scars (indented scars) on both cheeks. About 395 participants will receive either the gel or a saline placebo over 2 months and be followed for up to a year. The goal is to s…

This study tracks 125 German adults with early advanced Parkinson's disease who are prescribed a drug called Foslevodopa/Foscarbidopa. The goal is to see how well it improves motor symptoms, quality of life, and daily functioning in real-world settings. Participants receive the d…

This early-stage study tests a single dose of ABBV-547 in healthy adults to see if it is safe and how the body processes it. About 87 participants in the US and Japan will receive either the drug or a placebo. The study focuses on side effects and how the drug moves through the b…

This study follows 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax alone or with other drugs as part of their normal care. Researchers will track how well the treatment works, side effects, and costs in real-life settings across Austria, Germany, and …

This study looks at how a new drug, ABBV-722, changes the way the body processes five common medications. It involves 12 healthy adults who will take ABBV-722 along with a cocktail of other drugs. The goal is to check for side effects and measure drug levels in the blood to under…

This study looks at how doctors around the world use a 'treat-to-target' approach for people with Crohn's disease or ulcerative colitis. Researchers will review medical records from 2,000 adults over two years to see if this strategy leads to better outcomes. No new treatments or…

This early-stage study tests the safety of a new drug called ABBV-243 in healthy adults aged 18 to 60. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The goal is to gather safety information, not to…

This study looks at how three skin conditions—alopecia areata (patchy hair loss), vitiligo (white patches on skin), and hidradenitis suppurativa (painful boils)—affect daily life and emotional well-being. Researchers will survey nearly 2,800 teens and adults across multiple count…

This early-stage study tests how two oral drugs, ABBV-722 and upadacitinib, affect each other in the body and whether they are safe together. It involves 32 healthy adult volunteers who will take multiple doses. The goal is to gather safety and drug-level data, not to treat any d…

This study reviews medical records of 2,000 people with hepatitis C who took an 8-week course of glecaprevir/pibrentasvir. The goal is to see how safe and effective the treatment is for those also taking prescription or illegal drugs. Participants must not have had prior treatmen…

This early-stage study tests the safety of a new drug called ABBV-1042 in 48 healthy adults. Participants receive either the drug or a placebo, and researchers monitor for side effects and how the drug behaves in the body. The goal is to gather safety information, not to treat an…

This early-stage study looks at how the antifungal drug itraconazole changes the way the body processes ABBV-722. It involves 12 healthy adults who will take both drugs and have their blood levels measured. The goal is to gather safety and drug-level data, not to treat any diseas…

This early-stage study looks at how a new drug called ABBV-932 is processed and leaves the body in 8 healthy adult men. Participants take a single dose with a radioactive tracer so scientists can measure drug levels over time. The goal is to check safety and understand the drug's…

This early-stage study is testing the safety of an experimental drug called emraclidine in 40 healthy adults aged 65 and older. Researchers will give multiple doses of the drug or a placebo to see how the body processes it and whether it causes any side effects. The study does no…

This early-stage study tests whether multiple doses of an experimental drug, ABBV-722, affect the way a common birth control pill is processed in the body. About 16 healthy volunteers will take both the drug and the pill, and researchers will measure hormone levels in the blood. …

This study tracks the safety of two migraine medicines, Ubrelvy and Qulipta, when taken during pregnancy. Researchers will compare health outcomes for mothers and babies up to 12 months old among about 1,900 pregnant women with migraines in the U.S. and Canada. The goal is to see…